Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

Why does it matter? Less than one in eight Americans is metabolically healthy — and the test that reveals it costs almost nothing

Most people assume they're fine if they're not overweight, and assume they'll know something is wrong when their A1C rises. Dr. Chris Thompson — chief of interventional gastroenterology at Mass General Brigham and professor of medicine at Harvard — dismantles both assumptions. The gut is an active metabolic organ, and disease moves through it in a predictable five-step sequence that begins 15 years before standard labs catch it.

• Fewer than 12% of the total US population is metabolically healthy by clinical parameters — and less than a third of lean people qualify
• A fasting insulin test predicts type 2 diabetes 15 years before A1C rises, per the Whitehall 2 study — almost no clinician orders it
• A fiber-deficient diet doesn't just cause constipation: gut microbes eat your mucus layer, butyrate collapses, tight junctions fail, and bacterial fragments leak into the liver, triggering insulin resistance
• Every GLP-1 stop-restart cycle permanently shifts body composition toward fat and away from muscle, leaving you metabolically worse than before you started

No fiber means your gut microbiome will literally consume your intestinal lining

"Feed your microbes — or they're going to eat you," Thompson says. That's not a metaphor. When dietary fiber disappears, the microbes in your colon don't starve quietly. They turn to the next available substrate: the mucus layer protecting your gut wall.

The cascade is stepwise. Healthy gut bacteria ferment fiber into short-chain fatty acids, primarily butyrate. Butyrate feeds colonocytes — the cells lining your colon — and maintains the tight junction proteins that seal the gut barrier. Cut fiber, butyrate production collapses. Without butyrate, tight junction proteins go underproduced. Without tight junctions, the mucus layer erodes. Without the mucus layer, bacteria gain direct access to the epithelium. "It's a snowball effect," Thompson says.

This is why oral butyrate supplements don't substitute: butyrate needs to be produced inside the colon by fermenting bacteria to reach colonocytes. Taken orally, it's absorbed far upstream and never arrives where it matters.

The numbers: 25–40 grams of fiber per day is the clinical target. For resistant starch specifically — RS2, such as raw powdered potato starch — studies at 40 grams daily showed measurable improvements in both fatty liver and insulin sensitivity, independent of weight loss. That's not a regularity benefit. That's a structural metabolic intervention.

Fermented foods amplify the effect: they deliver live cultures and partially pre-digested substrates simultaneously, seeding the microbiome while also feeding it — a two-sided input dietary fiber alone doesn't provide.

Lean people are not protected — and a fasting insulin test catches the disease 15 years before your doctor looks

The NHANES study found that fewer than a third of lean Americans are metabolically healthy by clinical parameters. Across the full population, only 12% qualify. Thinness is not metabolic health.

Thompson lays out the five-step sequence of metabolic disease with clinical precision. It begins with caloric excess — typically glucose in Western diets — producing repeated insulin spikes. Chronically elevated fasting insulin is step two: the pancreas is flooding the system to pull glucose out of the bloodstream, because glucose is genuinely toxic at sustained elevations. Ectopic fat accumulation follows — fat deposited in cells that have no business storing it: liver, muscle, pancreas. Insulin resistance comes next. Finally, metabolic inflexibility: fasting no longer efficiently accesses fat stores, and carbohydrate intake doesn't cleanly shift the body into glucose-burning mode. "Your body doesn't know what to do," Thompson says. Beta cells begin to burn out. The damage compounds.

The Whitehall 2 study — a 10–15 year prospective study of British civil servants — showed that elevated fasting insulin predicted type 2 diabetes diagnosis across that entire window. Fifteen years of warning, almost entirely ignored.

The practical testing sequence: wear a CGM for 4–8 weeks to identify which foods spike glucose above 200 mg/dL and build a personal map of metabolic sensitivities. Then order a fasting insulin level. Calculate HOMA-IR — a formula combining fasting blood glucose and fasting insulin; above 2 signals insulin resistance. Each test is inexpensive and available today. Waiting for A1C to rise means waiting until beta cell loss and peripheral nerve damage are already underway — and both are irreversible.

LPS injected into healthy people induces insulin resistance — leaky gut is mechanistically confirmed

Researchers at Duke drew a hard line under the question. They injected LPS — lipopolysaccharide, a fragment of gram-negative bacterial cell membranes — directly into healthy volunteers. Inflammatory markers spiked. Clamp studies confirmed induced insulin resistance. No speculation required. "Increased gut permeability is 100% real," Thompson says.

The chain: when tight junctions fail, LPS crosses into portal circulation and heads directly to the liver. There it binds TLR4, activates NF-κB signaling, and fires an inflammatory cascade that directly impairs insulin signaling. This mechanism has been confirmed in both directions — pathologically via leaky gut, and experimentally via direct injection.

Biopsy studies make the structural picture concrete. Patients with MASH — metabolically associated steatohepatitis — had organoids showing disorganized, poorly developed tight junctions compared to healthy controls. Transcriptomics confirmed the problem went deeper than protein levels: MASH patients weren't generating the RNA to produce tight junction proteins. The suppression operated at the transcriptional level.

Tissue from obese and type 2 diabetic patients undergoing gastric bypass — resected and compared to bowel from cancer surgery controls — showed eightfold more natural killer cells and 1.5-fold more macrophages in the small bowel. A chronically inflamed gut in people whose distinguishing variable is primarily obesity.

The fiber-butyrate-tight junction chain runs the reverse: adequate dietary fiber → butyrate production in the colon → tight junction maintenance → LPS exclusion → no portal inflammation → no LPS-driven insulin resistance. Every link in the protective chain begins with feeding the microbiome.

Each GLP-1 on-off cycle permanently corrupts your body composition

About a third of weight lost on semaglutide is lean mass — mostly muscle. When you stop and regain the weight, fat comes back. The muscle does not. Run that cycle twice and you carry less muscle and more fat than when you started the drug. "You're taking your body composition and shifting it worse every cycle," Thompson says.

Over a million people per month are stopping GLP-1 drugs. Without a deliberate exit strategy, most are participating in an inadvertent recomposition experiment moving in the wrong direction. The clinical endpoint, compounded across repeated cycles, is sarcopenic obesity: low muscle mass, elevated fat, elevated metabolic risk — a profile more dangerous than the obesity they started with.

Thompson's required plan for anyone coming off a GLP-1 has three viable paths: micro-dose down to a maintenance level rather than stopping cold; bridge to an endoscopic procedure that addresses the underlying gut hormone profile; or — the most commonly skipped prerequisite — establish a resistance training routine before weight loss begins, so the body maintains a mechanical signal not to cannibalize muscle during caloric deficit.

Get a DEXA scan before starting. If lean mass is already low, the risk calculus changes substantially. Ozempic face and Ozempic butt are visible markers of a subtler systemic process — one that gets worse with each additional cycle.

Ablating the sick duodenum drops A1C by over a point — without surgery and without meaningful weight loss

Overfed mice don't just gain weight. Their small bowel gets physically longer, heavier, and more villous — the gut upregulates its own absorptive capacity in response to sustained caloric excess. The same adaptation has been confirmed in humans: obese and type 2 diabetic patients show dramatically longer villi, thicker bowel walls, and eightfold more natural killer cells in duodenal biopsies compared to cancer surgery controls. Tight junction proteins are disorganized and transcriptionally silenced.

The duodenum, Thompson argues, is not a passive tube in metabolic illness. It is an active disease organ, and resetting it changes the metabolic picture.

Duodenal mucosal resurfacing — delivered endoscopically through the mouth, same-day discharge, no abdominal incision — ablates the top layer of the duodenal mucosa. Stem cells regenerate a healthier lining. Clinical data: A1C drops by over a point in type 2 diabetic patients, even without significant weight loss. The metabolic correction precedes and exceeds what the scale shows.

Unpublished data Thompson describes suggests the procedure may also prevent weight regain after stopping GLP-1 therapy. The reset duodenum doesn't drive the same pro-inflammatory, pro-insulin-resistance signaling. Weight stays off. This positions duodenal mucosal resurfacing as a viable bridge strategy for the million-plus people per month who currently stop GLP-1 drugs and have no plan for what comes next.

HIIT mobilizes visceral fat through a receptor mechanism that zone 2 cardio cannot replicate

Visceral fat carries beta-adrenergic receptors and gonadotropic hormone receptors. That makes it specifically responsive to acute physiological stress in a way that subcutaneous fat is not. Zone 2 cardio is effective at burning fat as fuel during the session. It does not trigger the beta-adrenergic signal that liberates visceral fat from storage.

HIIT does. The acute stress of a high-intensity interval activates those receptors, and visceral fat mobilizes into circulation. It isn't oxidized immediately — during the work itself, the body is burning liver glycogen and muscle glycogen. But the mobilized fat circulates and is oxidized during recovery. The visceral depot shrinks because HIIT specifically targets the biological lock that holds it.

Thompson's exercise framework for patients moving through metabolic disease: resistance training first and throughout, to preserve lean mass and prevent the sarcopenic drift that caloric deficit accelerates; zone 2 to build baseline fat-oxidation capacity and cardiovascular health; HIIT as the dedicated mechanism for visceral fat reduction. None of the three substitutes for the others. They address different systems through different pathways, and all three are necessary for full metabolic rehabilitation.

A one-time pancreatic injection may make weekly GLP-1 shots permanently unnecessary

Current GLP-1 drugs saturate the area postrema with super-physiologic concentrations of a hormone that normally appears in tiny, nutrient-responsive pulses. A clinical trial now underway in the Netherlands takes a fundamentally different approach.

A viral vector carrying the GLP-1 gene is injected into the tail of the pancreas via endoscopic ultrasound — the same technology Thompson's lab developed to biopsy pancreatic tumors. The gene sits under the control of the insulin promoter: it activates only in beta cells, and only when the beta cell is already responding to a nutrient signal. When you eat, beta cells package insulin into secretory vesicles and release them. With the transgene active, GLP-1 is packaged into those same vesicles and released simultaneously — at the pancreas, where it acts locally, not from L cells in the distal gut traveling the long route through portal circulation.

Mouse data: semaglutide-treated mice and transgene mice lost comparable weight. When semaglutide was stopped, mice that then received the transgene returned to the same low settling point. Mice that received nothing regained all of it.

The pancreatic beta cell is terminally differentiated — the episomal DNA doesn't integrate and isn't lost to cell turnover. One injection, stable expression, permanent effect. Thompson has been involved in early-stage development of this approach from the outset.

The shift from chronic management to single correction is already underway

The recurring thread isn't any single drug or procedure — it's the direction of travel. Thompson's work, and the clinical trials he describes, point toward metabolic medicine becoming less about managing a deteriorating system indefinitely and more about identifying the broken biological signal and correcting it once. The duodenal reset, the gut hormone targeting, the fiber-butyrate-tight junction chain — all share the same underlying logic as the gene therapy trial: find the mechanism, intervene precisely, stop there.

The fasting insulin test costs almost nothing and has been available for decades. Almost no one orders it. That gap — between what is possible and what is routinely done — is where most of the preventable damage accumulates.

If the pancreatic gene therapy replicates in humans, the era of weekly injections as the default treatment for metabolic dysfunction may be shorter than anyone expects.

---

Topics: gut health, microbiome, GLP-1, obesity, metabolic disease, fiber, butyrate, leaky gut, tight junctions, insulin resistance, visceral fat, HIIT, endoscopic surgery, gene therapy, fasting insulin, CGM, duodenum, gastroenterology, weight loss